Cervical and anal HPV infection: cytological and histological abnormalities in HIV-infected women in Thailand

Reshmie A Ramautarsing1,2, Nittaya Phanuphak3, Surasith Chaithongwongwatthan4, Ferdinand WNM Wit2
Nipat Teeratakulpisarn3, Tippawan Pankam3, Piyaneed Rodbamrung3, Janneke H van de Wijgert, Joep MA Lange1,2
Praphan Phanuphak1,3,5, Vikrant V Sahasrabuddhe6, Stephen Kerr*1,7, Jintanat Ananworanich1,3,5,8,9
and the Thai Women’s HPV Study Group

1HIV Netherlands Australia Thailand Research Collaboration (HIVNAT), Bangkok, Thailand
2Department of Global Health, Academic Medical Center, University of Amsterdam, Amsterdam Institute for Global Health and Development (AIGHD), Amsterdam, the Netherlands
3Thai Red Cross AIDS Research Centre (TRCARC), Bangkok, Thailand
4Department of Medicine, Faculty of Obstetrics and Gynecology, Chulalongkorn University, Bangkok, Thailand
5Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
6Vanderbilt Institute for Global Health, Nashville, TN, USA, 7The Kirby Institute, University of New South Wales, Sydney, Australia
8SEARCH, Bangkok, Thailand, 9US Military HIV Research Program, Walter Reed Army Institute of Research; Henry M Jackson Foundation for the Advancement of Military Medicine, Maryland, USA

Abstract

Background: Women infected with human immunodeficiency virus (HIV) have higher rates of persistent infection with high-risk human papillomavirus (hr-HPV) and cervical and anal dysplasia. We describe the epidemiology of hr-HPV, and cervical and anal intra-epithelial abnormalities in HIV-infected women in Thailand.

Methods: HIV-infected women aged 18–49 years, either HAART-naïve or -experienced, were enrolled in Bangkok, Thailand. A demographic and sexual-risk behaviour questionnaire was administered and a pelvic examination with colposcopy was performed on every woman. Cervical and anal samples were tested for cytology and HPV genotyping.

Results: A total of 256 women were enrolled with a median [interquartile range (IQR)] age of 35 (32–40) years. Ninety (35.2%) had detectable cervical hr-HPV. Being post-menopausal was associated with increased risk for cervical hr-HPV, while years since HIV diagnosis and plasma HIV RNA <40 copies/mL were significantly associated with decreased risk in multivariable regression analyses. Abnormal cervical cytology was detected in 6.3%. Cervical biopsies that were taken from 99 women (39.3%) owing to abnormalities seen during colposcopy showed cervical intra-epithelial neoplasia (CIN) in 22.6%. The sensitivity of cervical cytology to detect CIN2+ was 10.0%. Among 102 women enrolled in the anal substudy, 18.8% had anal HPV infection and 11.1% had anal hr-HPV. Two women had abnormal anal cytology.

Conclusion: We found cervical and anal hr-HPV in 35.2% and 11.1% of Thai HIV-infected women, respectively. Moreover, the observed poor agreement between cervical cytology and histology results could indicate current cervical cancer screening programs for HIV-infected women might not be optimal for the detection of pre-neoplastic lesions.

Keywords: cervical HPV, anal HPV, women, Pap smear, HIV, Thailand

Introduction

Persistent infection with carcinogenic ‘high-risk’ types of the human papillomavirus (hr-HPV) is necessary for the development of cervical dysplasia and malignancies [1]. Worldwide, about 70% of all cervical cancers are caused by infection with HPV type 16 or 18 [2]. Cervical cancer is a preventable disease: in countries where screening programmes using Pap smears have been implemented, prevalence of invasive cervical cancer and cervical cancer-related mortality has reduced dramatically [3,4]. In developing countries, the implementation of widespread use of prophylactic vaccine, as well as cervical cancer screening programmes, is difficult owing to financial and logistic restrictions, and therefore the burden of disease is disproportionately high [5].

Women infected with HIV have higher rates of cervical HPV infection and more rapid progression to high-grade squamous intra-epithelial lesions (HSIL) and cervical cancer [6,7]. Furthermore, anal HPV infection in HIV-infected women is highly prevalent, with some studies reporting rates of 80–90% [8,9].

There are approximately 1.4 million women infected with HIV in Asia [10]; however, data on cervical and anal HPV are severely lacking. In Thailand, approximately 250,000 women are currently infected with HIV, but information on the burden of cervical HPV infection in this population is scarce, and data on anal HPV infection in this population are not available. We conducted this study to assess the prevalence of cervical and anal HPV infection in HIV-infected women in Thailand.

Methods

This is a cross-sectional analysis of cervical and anal HPV and intra-epithelial neoplasia of a study conducted at the Thai Red Cross AIDS Research Centre, Bangkok, Thailand. Non-pregnant, HIV-infected women aged 18–49 years were invited to enrol if they did not have a history of cervical cancer, hysterectomy or current cervical infection. HAART-naïve women were eligible for enrolment if they had a CD4 cell count >350 cells/mm³, whereas HAART-experienced women were eligible if they had been using antiretroviral therapy for at least 6 months. After providing informed consent, an extensive questionnaire to assess demographics and sexual behaviour was administered by a trained study nurse. Blood samples for CD4 cell count and HIV RNA were collected. A pelvic exam was performed by a gynaecologist, during which cervical samples for cytology and HPV DNA testing were taken. At the same visit, prior to Pap smear results, colposcopy was performed on all patients, including application of acetic acid, and cervical biopsies were taken as necessary. A sub-study to assess anal HPV was also performed. Separate consent was required; patients who provided consent answered...
### Table 1. Baseline characteristics by cervical hr-HPV status (n=256). Characteristics are given in n (%) or median (IQR) where appropriate

| Characteristic                                      | Overall (n=256) | No hr-HPV infection (n=166) | hr-HPV infection (n=90) | P value |
|-----------------------------------------------------|-----------------|-----------------------------|-------------------------|---------|
| Age (years)                                         | 35 (32–40)      | 36 (33–40)                  | 34 (30–40)              | 0.09    |
| Marital status                                      |                 |                             |                         |         |
| Unmarried                                           | 8 (3.1)         | 3 (1.8)                     | 5 (5.6)                 | 0.11    |
| Married                                             | 195 (76.2)      | 128 (77.1)                  | 67 (74.4)               |         |
| Separated/divorced                                  | 32 (12.5)       | 18 (10.8)                   | 14 (15.6)               |         |
| Widowed                                             | 21 (8.2)        | 17 (10.2)                   | 4 (4.4)                 |         |
| Age at marriage (years)                             | 21 (19–26)      | 21 (18–25)                  | 21 (19–27)              | 0.33    |
| HIV-status current partner                          |                 |                             |                         |         |
| Uninfected                                          | 88 (34.4)       | 61 (36.7)                   | 27 (30)                 | 0.21    |
| Infected                                            | 79 (30.9)       | 49 (29.5)                   | 30 (33.3)               |         |
| No partner                                          | 45 (17.6)       | 33 (19.9)                   | 12 (13.3)               |         |
| Unknown status                                      | 44 (17.2)       | 23 (13.9)                   | 21 (23.3)               |         |
| Level of education                                  |                 |                             |                         |         |
| No formal education                                 | 5 (2.0)         | 3 (1.8)                     | 2 (2.2)                 | 0.81    |
| Primary school                                      | 91 (35.5)       | 56 (33.7)                   | 35 (38.9)               |         |
| Secondary school                                    | 99 (38.7)       | 69 (41.6)                   | 30 (33.3)               |         |
| Tech. certificate                                   | 25 (9.8)        | 15 (9.0)                    | 10 (11.1)               |         |
| Bachelor                                            | 33 (12.9)       | 20 (12.0)                   | 13 (14.4)               |         |
| Masters                                             | 3 (1.2)         | 3 (1.8)                     | —                       |         |
| Total monthly family income (THB)                  |                 |                             |                         | 0.36    |
| ≤20,000                                             | 203 (79.2)      | 136 (82.9)                  | 67 (74)                 |         |
| >20,000                                             | 48 (18.9)       | 27 (16.3)                   | 21 (23.3)               |         |
| Refused to answer                                   | 5 (1.9)         | 3 (1.8)                     | 2 (2.2)                 |         |
| Current smoking                                     | 6 (2.3)         | 2 (1.2)                     | 4 (4.4)                 | 0.12    |
| Past smoking                                        | 19 (7.5)        | 10 (6.1)                    | 9 (10.1)                | 0.25    |
| Current alcohol use                                 | 29 (11.5)       | 14 (8.6)                    | 15 (16.7)               | 0.054   |
| Past alcohol use                                    | 61 (24.2)       | 35 (21.6)                   | 26 (28.9)               | 0.20    |
| Post-menopausal                                     | 9 (3.5)         | 2 (1.2)                     | 7 (7.9)                 | 0.01    |
| Age first intercourse (years)                       | 19 (18–23)      | 19 (18–23)                  | 19 (18–22)              | 0.46    |
| Number sexual partners last 30 days                 |                 |                             |                         | 0.45    |
| 0                                                   | 43 (16.8)       | 29 (17.5)                   | 14 (15.6)               |         |
| 1                                                   | 202 (79.2)      | 134 (80.7)                  | 68 (76.4)               |         |
| 2–4                                                | 3 (1.2)         | 0                           | 3 (3.4)                 |         |
| >5                                                  | 5 (2.0)         | 3 (1.8)                     | 2 (2.2)                 |         |
| Lifetime number sexual partners                     |                 |                             |                         | 0.45    |
| 1                                                   | 67 (26.2)       | 45 (27.1)                   | 22 (24.4)               |         |
| 2–4                                                | 132 (51.8)      | 89 (53.6)                   | 43 (48.3)               |         |
| 5–20                                               | 36 (14.1)       | 21 (12.7)                   | 15 (16.9)               |         |
| >20                                                 | 8 (3.1)         | 4 (2.4)                     | 4 (4.5)                 |         |
| Commercial sex work                                 | 15 (5.9)        | 6 (3.6)                     | 9 (10.1)                | 0.052   |
| Current OC use                                      | 25 (10.1)       | 13 (8.1)                    | 12 (13.6)               | 0.18    |
| Past OC use                                         | 177 (73.4)      | 109 (69.4)                  | 68 (81.0)               | 0.14    |
| Condom use during VI with regular partner           |                 |                             |                         | 0.03    |
| n = 223                                             | 189 (84.8)      | 128 (88.9)                  | 61 (77.2)               |         |
| Consistent                                          | 189 (84.8)      | 128 (88.9)                  | 61 (77.2)               |         |
| Inconsistent                                        | 19 (8.5)        | 7 (4.9)                     | 12 (15.2)               |         |
| Never                                               | 15 (6.7)        | 9 (6.3)                     | 6 (7.6)                 |         |
| Current genital ulcer                               | 7 (2.8)         | 1 (0.6)                     | 6 (6.6)                 | 0.009   |
| Past genital ulcer                                  | 19 (7.5)        | 8 (4.9)                     | 11 (12.2)               | 0.08    |
| Current genital warts                               | 1 (0.4)         | —                           | 1 (1.1)                 | 0.58    |
| Ever genital warts                                  | 8 (3.2)         | 2 (1.2)                     | 6 (6.7)                 | 0.034   |
| Time since HIV diagnosis (years)                    | 7.0 (4.9–10.1)  | 7.5 (5.4–10.5)              | 5.9 (4.0–8.3)           | 0.0001  |
| HIV transmission category                           |                 |                             |                         | 0.18    |
| Sex with husband                                    | 237 (92.6)      | 156 (94.0)                  | 81 (90.0)               |         |
| Other                                               | 18 (7.0)        | 9 (5.5)                     | 9 (10.0)                |         |
| Current CD4 count (cells/mm$^3$)                    | 482 (376–623)   | 488 (378–617)               | 464 (372–651)           | 0.81    |
| CD4 count <350 cells/mm$^3$                         | 46 (18.1%)      | 28 (17.1%)                  | 18 (20.0%)              | 0.56    |
| HAART use, n (%)                                    | 189 (73.8)      | 129 (77.7)                  | 60 (66.7)               | 0.055   |
| Time since start HAART (years)                      | 4.9 (3.1–6.3)   | 5.0 (3.2–6.4)               | 4.3 (2.8–6.2)           | 0.31    |
| Plasma HIV RNA <40 copies/mL                        |                 |                             |                         |         |
| All patients                                        | 149/238 (62.6)  | 109/159 (68.6)              | 40/79 (50.6)            | 0.006   |
| On HAART                                            | 145/180 (80.6)  | 107/124 (86.3)              | 38/56 (67.9)            | 0.004   |

THB: Thai Baht, OC: oral contraceptives, VI: vaginal intercourse, HAART: highly active antiretroviral therapy.
questions regarding anal intercourse, and underwent anal examination, during which, samples for anal cytology and HPV DNA testing were collected. High-resolution anoscopy by an experienced physician was offered to all women with evidence of abnormalities from anal cytology. The study was approved by Chulalongkorn University Institutional Review Board. Informed consents were obtained in Thai language from all patients.

Cervical cytology and histology

Cytology was performed on cervical specimens using conventional Pap smear, and classified according to the 2001 revised Bethesda system [11] as negative for intra-epithelial lesion or malignancy, atypical squamous cells of undetermined significance (ASC-US), low-grade squamous intra-epithelial lesions (LSIL), high-grade squamous intra-epithelial lesions (HSIL) and squamous cell carcinoma. Histological diagnoses were classified as normal and cervical intra-epithelial neoplasia (CIN) grades 1–3. The Pap smears and cervical biopsies were read by gynaecological pathologists at the Chulalongkorn University Hospital, Bangkok, Thailand. Abnormal slides and a randomly selected 10% of normal slides were re-read by a senior cytopathologist, who gave the final result. Samples that were found to be unsatisfactory were excluded from analysis.

Cervical HPV testing

Liquid-based cytology samples were screened first with the Amplicor HPV test (Roche Molecular Systems, Alameda, CA, USA), a polymerase chain reaction (PCR) testing positive if at least one of 13 hr-HPV types is present (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68). Invalid samples (negative internal control) were excluded from analysis. Positive samples were processed further using the Linear Array HPV genotyping test (Roche Molecular Systems, Alameda, CA, USA), which detects up to 37 HPV genotypes (the above mentioned 13 hr-HPV types, and additionally 24 other HPV types that are possibly carcinogenic, non–carcinogenic or of unknown carcinogenicity (6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 66, 67, 69, 70, 71, 72, 73, 81, 82, 83, 84, IS39 and CP6108)).

Anal cytology

Cytology was performed on anal specimens by conventional Pap smear, and were classified according to the 2001 revised Bethesda system [11] as described above. The anal Pap smears were read by gynaecological pathologists at the Chulalongkorn University Hospital, Bangkok, Thailand. Abnormal slides and a randomly selected 10% of normal slides were re-read by a senior cytopathologist, who gave the final result. Samples that were found to be unsatisfactory were excluded from analysis. Women with squamous cell abnormalities were offered high-resolution anoscopy at our centre.

Anal HPV testing

Anal swabs were collected and were tested for HPV using the Linear Array HPV genotyping test as described above.

Statistical methods

Statistical analysis was conducted using Stata Version 12 (Statacorp, College Station, TX, USA). Demographic characteristics were analysed using descriptive statistics [frequency and percentage or median and interquartile range (IQR) as appropriate]. Women without cervical hr-HPV infection were compared to women with cervical hr-HPV infection using Chi-squared tests or Kruskal–Wallis tests as appropriate. Factors associated with cervical hr-HPV infection were analysed using univariable and multivariable logistic regression analyses using a backward selection process retaining terms in the model significant at P<0.05.

Results

Demographic, sexual and HIV characteristics

A total of 256 women were enrolled, of whom 90 (35.2%) had cervical hr-HPV using the Amplicor HPV test (Table 1). Overall, the median age was 35 years (IQR 32–40 years). The majority of women (76.2%) were married. Very few women were past or current smokers (9.8%); this did not differ between women with, and without cervical hr-HPV. The median age at first sexual intercourse was 19 years, and a minority (n=15, 5.9%) reported current or ever commercial sex work. A total of 189 (73.8%) women were currently using HAART for a median time of 4.9 years, the median time since HIV diagnosis was 7.0 years, 7.5 years among women without cervical hr-HPV and 5.9 years for women with cervical hr-HPV (P<0.001). The majority of women (92.6%) reported to have been infected with HIV by their current or previous husband. Median CD4 cell counts were similar between HAART-naïve (460 cells/mm³; IQR 396–584 cells/mm³) and HAART–experienced women (CD4 483 cells/mm³; IQR 359–626 cells/mm³).

Prevalence of cervical hr-HPV

After excluding three (1.2%) invalid samples, we found cervical hr–HPV infection in 90 (35.6%) women using the Amplicor HPV test. These samples were then processed to identify the HPV genotypes present and the results are shown in Table 2.

Of the 90 women, no HPV DNA was detected with the Linear Array test for 16. The most common hr-HPV genotypes identified were HPV-51 (n=12, 4.7%), HPV-58 (n=12, 4.7%), HPV-16 (n=11, 4.3%), HPV-52 (n=11, 4.3%), HPV-18 (n=6, 2.3%), HPV-33 (n=6, 2.3%) and HPV-39 (n=6, 2.3%) (Figure 1). Because the probe that hybridises HPV-52 in the Linear Array test is cross-reactive with HPV types 33, 35 and 58, we examined further for the presence of one of these three types in the samples positive for HPV-52. HPV-52 was present exclusively in 10 (3.9%), while in one (0.4%) sample HPV-33 was also present.

Cervical cytology and histology

After excluding four unsatisfactory samples (1.6%), cytological results were available for 252 women. Of the samples that were satisfactory for evaluation, organisms were detected in 15 samples (5.9%), 56 samples (22.2%) lacked an endocervical/transformation zone component and 42 samples (16.7%) were partially obscured by blood. Furthermore, 97 (38.5%) samples showed reactive cellular changes associated with inflammation. Of the 252 samples, 236 (93.7%) were negative for intra-epithelial abnormalities, nine (3.6%) had ASCUS, six (2.4%) had LSIL and one (0.4%) had HSIL. All women underwent colposcopy, but biopsies were performed on 99/252 (39.3%) of
the women owing to colposcopic abnormalities. The biopsies showed no intra-epithelial abnormalities in 42 women, CIN1 in 47 (18.7%), CIN2 in two (0.8%) and CIN3 in eight women (3.2%). Of the 57 women with CIN1+, 45 (78.9%) had normal cytology, five (8.8%) had ASCUS, six (10.5%) had LSIL and one (1.8%) had HSIL (Table 3), resulting in a Cohen’s kappa of 0.11. The sensitivity of abnormal cervical cytology from ASCUS and above to detect histology confirmed CIN1+ was 12.7% (95%CI 5.3–24.5%), and the corresponding sensitivity to detect CIN2+ was 10.0% (95%CI 0.3–44.5%). The specificity was 100% (95%CI 91.8–100%) and 100% (95%CI 95.9–100%), respectively.

Risk factors for cervical hr-HPV infection

Factors that were significantly associated with cervical hr-HPV infection in the unvariable regression analysis were being post-menopausal, years since HIV diagnosis, plasma HIV RNA <40 copies/mL, self-reported inconsistent condom use during vaginal intercourse, current or ever having genital ulcer (self-reported) and ever having genital warts (self-reported). These factors were included in a multivariable regression model, except for self-reported genital ulcers and genital warts due to collinearity. In this multivariable regression model, being post-menopausal (OR 12.47, 95%CI 2.34–66.29, P=0.003), years since HIV diagnosis (OR 0.88, 95%CI 0.81–0.96, P=0.003) and plasma HIV-RNA <40 copies/mL (OR 0.42, 95%CI 0.23–0.79, P=0.007) remained significantly associated with cervical hr-HPV infection (Table 4). After adding self-reported genital ulcers and genital warts to this model, both factors were significantly associated with the presence of hr-HPV (OR 11.75, 95%CI 1.14–121.19, P=0.038 and OR 6.82, 95%CI 1.07–43.38, P=0.042, respectively). However, the OR for the other risk factors from the multivariable model did not significantly change (data not shown).

Anal sub-study

A total of 102 women consented to the anal sub-study. Of these, four (3.9%) reported to ever having engaged in anal intercourse, of whom one reported consistent condom use during anal intercourse, one inconsistent condom use, and two never having used condoms during anal intercourse. Five unsatisfactory Pap smears were excluded (4.9%). Two women showed abnormalities on anal cytology: one ASCUS and one LSIL–AIN. Both women were offered high-resolution anoscopy at our centre. The woman with ASCUS did not return for further examination. The woman with LSIL–AIN underwent high-resolution anoscopy during which a biopsy was taken. Histological analysis of this specimen showed anal condylomata.

After excluding 12 (11.8%) invalid HPV test results, 90 anal HPV results were available. Anal HPV infection was detected in 17 women (18.8%); of whom 10 (11.1%) had hr-HPV. Among these 90 women who had cervical and anal HPV results available, 26 (28.9%) had only cervical hr-HPV infection, seven (8%) had only anal HPV-infection, and nine (10%) had cervical as well as anal HPV infection (Table 5). In women with anal hr-HPV, the odds of having cervical hr-HPV was 2.03 (95%CI 0.67–6.11, P=0.21).

Discussion

We found cervical hr-HPV infection in 35.2% of HIV-infected women in Thailand. Furthermore, we found cervical squamous intra-epithelial lesions of any grade in 6.3%, as determined by Pap smear. All women underwent colposcopy, which was abnormal in 99 women and, as a result, histological specimens were taken. Histology revealed that 22.6% of women had CIN. To our knowledge, we also provide the first data on anal HPV infection in HIV-infected women in Asia. Among 102 women in our sub-study, we found anal hr-HPV infection in 11.1%, and abnormal anal cytology in two women.

The prevalence of cervical hr-HPV in our cohort is similar to the prevalence of 38.6% reported from a previous study in HIV-infected women in Bangkok [12], but lower than the prevalence in studies in HIV-infected women from other countries, which ranged from 46.7% to 70% [9,13].

Furthermore, in our cohort HPV types 51, 58, 16, 52, 18, 33 and 39 were the most common high-risk types found. This is consistent with a recent study involving over 5,906 Thai women, where HPV 52, 16 and 51 were the most prevalent cervical HPV types found, although whether any of the women in this latter study were HIV-infected was not reported [14]. HIV-infected women might have a different HPV type distribution in cervical dysplasia compared to HIV-uninfected women, with HPV types 18, 33, 51, 52 and 58 found more commonly than HPV 16 [15,16]. While other studies do not confirm this, nevertheless they tend to show a higher HPV prevalence in HIV-negative women [17–19]. The clinical significance of this, and the potential impact on HPV-vaccine efficacy remains to be elucidated.

In our and other resource-limited settings, Pap smear for cervical cancer screening is not routinely performed owing to logistical and financial restrictions. Testing for the presence of hr-HPV as a triage has been suggested for settings where the availability of histopathological analysis is limited, due to the higher sensitivity to detect lesions with a high potential for malignant transformation, and has been shown to be feasible for these settings [20,21]. We found a poor agreement between cytology and histology findings, and the sensitivity of Pap smears to detect either CIN1+ or CIN2+ in our study was rather low. This is in line with other reports suggesting that routine colposcopy should be performed in HIV-infected women [22–24]. The quality of cytology is dependent upon various operational and logistical requirements, which are often not optimal in resource-limited settings. However, in our study we assured quality control by the re-reading of all abnormal slides and a random selection of normal slides by a second cytopathologist. Collection technique significantly influences the sensitivity of cervical cytology. Although the rate of unsatisfactory samples was relatively low (four samples), 22.2% of samples lacked an endocervical/transformation zone component. An endocervical/transformation zone component is not required by the Bethesda criteria for a sample to be classified as satisfactory, but its presence improves the overall specimen quality [11]. The importance of this component is controversial, but it has been
Table 3. Cytology versus histology

| Biopsy                          | Total | Normal | ASC-US | LSIL | HSIL |
|---------------------------------|-------|--------|--------|------|------|
| ND                              | 153   | 150    | 3      | 0    | 0    |
| No intraepithelial abnormalities| 42    | 41     | 1      | 0    | 0    |
| CIN                             | 47    | 40     | 2      | 5    | 0    |
| CIN2                            | 2     | 1      | 1      | 0    | 0    |
| CIN3                            | 8     | 4      | 2      | 1    | 1    |
| Total                           | 236   | 9      | 6      | 1    | 1    |

ND: not done; CIN1: cervical intra-epithelial neoplasia grade 1; CIN2: cervical intra-epithelial neoplasia grade 2; CIN3: cervical intra-epithelial neoplasia grade 3; ASC-US: atypical squamous cells of undetermined significance; LSIL: low grade squamous intra-epithelial lesions; HSIL: high grade squamous intra-epithelial lesions

Table 4. Unadjusted and adjusted odds ratios for factors associated with cervical hr-HPV

| Characteristic                  | Unadjusted OR (95% CI) | P value | Adjusted OR (95% CI) | P Value |
|---------------------------------|------------------------|---------|----------------------|---------|
| Age (years)                     | 0.96 (0.92–1.01)       | 0.11    |                      |         |
| Age at marriage (years)         | 1.03 (0.98–1.08)       | 0.31    |                      |         |
| Current smoking                 | 3.77 (0.68–20.98)      | 0.13    |                      |         |
| Past smoking                    | 1.73 (0.68–4.44)       | 0.25    |                      |         |
| Current alcohol use             | 2.13 (0.98–4.64)       | 0.057   |                      |         |
| Past alcohol use                | 1.47 (0.62–2.66)       | 0.20    |                      |         |
| Postmenopausal                  | 7.00 (1.42–34.45)      | 0.02    | 12.47 (2.34–66.29)   | 0.003   |
| HAART use                       | 0.57 (0.32–1.02)       | 0.056   |                      |         |
| Years since HIV diagnosis       | 0.87 (0.80–0.94)       | <0.001  |                      | 0.003   |
| Years since start HAART         | 0.93 (0.83–1.06)       | 0.29    |                      |         |
| Current plasma HIV RNA <40 copies/mL | 0.47 (0.27–0.82)   | 0.008   | 0.42 (0.23–0.79)     | 0.007   |
| Current CD4 count               |                        |         |                      |         |
| <350 cells/mm³ (reference)      | 1.0                    |         |                      |         |
| 350–499 cells/mm³               | 0.87 (0.42–1.79)       | 0.70    |                      |         |
| ≥500 cells/mm³                  | 0.79 (0.39–1.60)       | 0.51    |                      |         |
| Marital status                  |                        |         |                      |         |
| Unmarried (reference)           | 1.0                    |         |                      |         |
| Married                         | 0.31 (0.07–1.35)       | 0.12    |                      |         |
| Separated/divorced              | 0.47 (0.09–2.29)       | 0.35    |                      |         |
| Widowed                         | 0.14 (0.02–0.85)       | 0.03    |                      |         |
| HIV status partner              |                        |         |                      |         |
| HIV-uninfected (reference)      | 1.0                    |         |                      |         |
| HIV-infected                    | 1.38 (0.73–2.63)       | 0.32    |                      |         |
| No partner                      | 0.82 (0.37–1.83)       | 0.63    |                      |         |
| Unknown                         | 2.06 (0.98–4.35)       | 0.057   |                      |         |
| Lifetime number of sex partners |                        |         |                      |         |
| 1 (reference)                   | 1.0                    |         |                      |         |
| 2–9                             | 1.08 (0.59–1.97)       | 0.81    |                      |         |
| 20–100                          | 1.02 (0.09–11.90)      | 0.99    |                      |         |
| More than 100                   | 3.07 (0.48–19.72)      | 0.24    |                      |         |
| Refused                         | 1.46 (0.42–5.13)       | 0.55    |                      |         |
| Number of sex partners in last 30 days |                        |         |                      |         |
| 0 (reference)                   | 1.0                    |         |                      |         |
| 1–4                             | 1.10 (0.55–2.21)       | 0.79    |                      |         |
| 5–19                            | 0.69 (0.07–7.25)       | 0.76    |                      |         |
| Ever commercial sex work        | 2.65 (0.89–7.83)       | 0.08    |                      |         |
| Condom use during vaginal intercourse |                    |         |                      |         |
| Consistent (reference)          | 1.0                    |         |                      |         |
| Inconsistent                    | 3.60 (1.35–9.59)       | 0.01    |                      |         |
| Never                           | 1.40 (0.48–4.11)       | 0.54    |                      |         |
| Current genital ulcer           | 11.64 (1.38–98.29)     | 0.02    |                      |         |
| Ever genital ulcer              | 2.72 (1.05–7.02)       | 0.04    |                      |         |
| Ever genital wart               | 5.86 (1.16–29.65)      | 0.03    |                      |         |

OR: odds ratio; 95%CI: 95% confidence interval; HAART: highly active antiretroviral therapy
found that abnormal cells are less often found in samples lacking the endocervical/transformation zone component [25]. This could explain the lower sensitivity of cervical cytology found in our study. We did not perform wet mount in this study, and therefore it might have been possible that local inflammation leading to cellular obscuration played an important role. Further research on screening tests to evaluate ideal combinations of sensitivity and specificity must be pursued, such as hr-HPV testing and/or the use of other biomarkers such as HPV E6/E7 oncoprotein in HIV-infected women in resource-limited settings, and particularly in Thailand [26].

Women with undetectable plasma HIV RNA had a decreased risk of having cervical hr-HPV infection. Immune recovery after starting HAART, resulting in a better clearance of HPV-infection could explain this phenomenon [27]. Although the use of HAART as a factor was not significantly associated with cervical hr-HPV in our cohort, this difference might be explained by an adherence effect, and persistent undetectable viral load may be a more appropriate marker. Minkoff et al. investigated the effect of adherent and effective HAART use on the prevalence of cervical HPV infection and squamous intra-epithelial lesions [28]. Adherent HAART use was defined as self-reported use of HAART as prescribed ≥95% of the time, while effective HAART use was defined as a reduction in HIV RNA by >90% or to undetectable levels. In adherent HAART users, the prevalence of cervical hr-HPV infection was reduced in multivariable models, although the association was not significant. In our study, HAART use was not associated with prevalent hr-HPV in multivariate models, but an undetectable viral load, which reflects good adherence in the period before testing, was associated with a significant 58% reduction in prevalent hr-HPV.

Longer duration of diagnosed HIV-infection was also associated with a decreased risk of cervical hr-HPV infection. This could reflect a higher likelihood of these women to have started HAART, leading to immune recovery, and facilitating the clearance of HPV infection. However, a change in sexual risk behaviour after diagnosis of HIV-infection cannot be excluded [25].

Although we were limited by the sample size, our estimates indicate that post-menopausal women had an increased risk of cervical hr-HPV infection. This is in line with previous evidence, showing a ‘second peak’ of HPV infection among older, post-menopausal women, in addition to the first peak in adolescence [29]. Likely explanations for this are a weakened immune response with older age, hormonal changes leading to higher vulnerability of the epithelium, or changes in sexual activity [30].

Table 5. HPV genotype distribution in women with anal and cervical HPV infection

| Age (years) | CD4 (cells/mm³) | HAART use | Anal HPV types | Anal Pap | Cervical HPV types |
|------------|-----------------|-----------|----------------|---------|-------------------|
| 26         | 317             | +         | 16             | Neg     | 16                |
| 34         | 303             | +         | 33, 66         | Neg     | 33                |
| 33         | 465             | +         | 18, 51, 52     | Neg     | 51, 53            |
| 35         | 352             | +         | 59             | Neg     | 59, 62, 71        |
| 32         | 445             | -         | 16, 58, 59, 73, CP6108 | Neg | 16, 54, 58, 70, 73, CP6108 |
| 21         | 396             | -         | 45             | Neg     | 16, 40, 45, 58, 59, 66 |
| 44         | 394             | -         | 16             | Neg     | 16                |
| 25         | 395             | -         | 62             | Neg     | 52, 53, 55, 56, 62 |
| 29         | 728             | -         | 72             | Neg     | High-risk positive, could not be typed |

HAART: highly active antiretroviral therapy; Neg: negative for intra-epithelial abnormalities

Official anal cancer screening guidelines have not been adopted, but the routine screening of HIV-infected men and women with anal Pap smear has been suggested [31]. In our cohort the prevalence of anal HPV infection and of anal hr-HPV infection was 18.8% and 11.1%, respectively, which is relatively low compared to the recently reported results of the Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (the SUN study) [9]. In the SUN cohort, 90% of HIV-infected women had anal HPV, and 85% had anal hr-HPV infection. However, the SUN cohort was quite different from ours: 52% of women were current smokers, compared to 2.3% in our cohort, and 38% of the women in the SUN study reported a history of anal intercourse, compared to 3.9% in our cohort. Furthermore, we found a relatively low prevalence of cytological abnormalities, which may be explained by the fact that anal cytology, similar to cervical cytology, has low sensitivity to detect abnormalities [32] and that we only performed high-resolution anoscopy on women who had abnormal anal cytology. The Women's Interagency HIV Study (WIHS) cohort recently reported 16% prevalence of anal intra-epithelial neoplasia in HIV-infected women, which is similar to the prevalence of CIN in the same cohort [8].

Our study has several limitations. Although the colposcopy performed in all women was a strength of our study, biopsy was only performed in women with abnormal findings; hence the sensitivity and specificity estimates are not adjusted for verification bias. Furthermore, longitudinal data are needed to elucidate the influence of suppressed plasma HIV RNA on the acquisition or clearance of cervical hr-HPV infection.

In conclusion, we found a prevalence of cervical hr-HPV of 35% in Thai HIV-infected women; with virologically suppressed women and women with a longer time since HIV diagnosis having a lower risk of having cervical hr-HPV infection, indicating that early diagnosis and treatment of HIV is beneficial. Furthermore, we found a poor agreement between the results of cervical Pap smear testing and results of cervical histology, suggesting Pap smear for cervical cancer screening might not be an optimal method for cervical cancer screening in HIV-infected women in our setting. Further research on evaluating efficacy of HPV-based screening among HIV-infected women in our setting is warranted.

Acknowledgements

Thai Women's HPV Study Group, HIVNAT: Kiat Ruxunthath, Sasiwimol Ubolyam, June Ohata; Thai Red Cross AIDS Research Centre: Piranun Hongchokiat; SEARCH Thailand: Nitiya Chomchey; King Chulalongkorn Memorial Hospital: Sunee
Sirivichayakul, Somchai Niruthisard; Vanderbilt Institute of Global Health: Sten Vermund, Andrea Li

This study is funded by the National Research University Project of CHE, the Ratchadaphiskomphot Endowment Fund (Project number HR1161A), and the HIVNAT Research Collaboration. RAR is supported by the ART AIDS Foundation.

We are grateful to all the study participants, and all staff at HIVNAT, Thai Red Cross AIDS Research Centre and SEARCH Thailand.

Conflicts of interest
None were declared.

Sources of support:
National Research University of CHE, Thailand; the Ratchadaphiskomphot Endowment Fund, Thailand and the HIVNAT Research Collaboration, Thailand.

Disclaimer
The views expressed are those of the authors and should not be construed to represent the positions of the US Army or the Department of Defense.

References
1. Bosch FX, Lorincz A, Munoz N et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244–265.
2. Bosch FX, Burchell AN, Schiffman M et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2006; 26 Suppl 10: K1–16.
3. Cox B, Skirke DC. Projections of cervical cancer mortality and incidence in New Zealand: the possible impact of screening. J Epidemiol Community Health 1992; 46: 373–377.
4. Peter J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004; 364: 249–256.
5. Jamal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90.
6. Ahdein L, Klein RS, Burk R et al. Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis 2001; 184: 682–690.
7. Frisch M, Bigger RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000; 92: 1500–1510.
8. Hossel NA, Holly EA, Efird JT et al. Anal intraepithelial neoplasia in a multisite study of HIV-infected and high-risk HIV-uninfected women. AIDS 2009; 23: 59–70.
9. Kojic EM, Cu-Uvin S, Conley L et al. Human papillomavirus infection and cytologic abnormalities of the anus and cervix among HIV-infected women in the study to understand the natural history of HIV/AIDS in the era of effective therapy (the SUN study). Sex Transm Dis 2011; 38: 253–259.
10. UNAIDS. Report on the Global AIDS Epidemic. 2013. Available at: www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf (Accessed March 2015).
11. Solomon D, Davey D, Kurman R et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287: 2114–2119.
12. Sivongrangsop P, Ballen LJ, Chaovavanich A et al. Screening HIV-infected women for cervical cancer in Thailand: findings from a demonstration project. Sex Transm Dis 2007; 34: 104–107.
13. Dartell M, Rasch V, Kahesa C et al. Human papillomavirus prevalence and type distribution in 3603 HIV-positive and HIV-negative women in the general population of Tanzania: the PROTECT study. Sex Transm Dis 2012; 39: 201–208.
14. Kantathavorn V, Mahidol C, Sritana N et al. Genotypic distribution of human papillomavirus (HPV) and cervical cytology findings in 5906 Thai women undergoing cervical cancer screening programs. Infect Agent Cancer 2015; 10: 7.
15. Luque AE, Jabeen M, Messing S et al. Prevalence of human papillomavirus genotypes and related abnormalities of cervical cytological results among HIV-1–infected women in Rochester, New York. J Infect Dis 2006; 194: 428–434.
16. Saltanabudathe VY, Meanhumamu MH, Vermund SH et al. Prevalence and distribution of HPV genotypes among HIV-infected women in Zambia. Br J Cancer 2007; 96: 1480–1483.
17. Danwch L, Canadas MP, Sierra G et al. Human papillomavirus genotype distribution and human papillomavirus 16 and human papillomavirus 18 genomic integration in invasive and in situ cervical carcinoma in human immunodeficiency virus-infected women. Int J Gynecol Cancer 2011; 21: 1486–1490.
18. Vuyet HD, Nirgurau G, Moodley M et al. Prevalence of human papillomavirus in women with invasive cervical carcinoma by HIV status in Kenya and South Africa. Int J Cancer 2011; 131: 949–955.
19. Maranga IO, Hampson L, Oliver AW et al. HIV infection alters the spectrum of HPV subtypes found in cervical smears and carcinomas from Kenyan women. Open Viral J 2013; 7: 19–27.
20. Qiao YL, Sellors JW, Eder PS et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008; 9: 929–936.
21. Sankaranarayanan R, Nene BM, Shahab SS et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360: 1385–1394.
22. Maiman M, Fruchter RG, Sedin A et al. Prevalence, risk factors, and accuracy of cytologic screening for cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Gynecol Oncol 1998; 68: 233–239.
23. Robinson WR, Barnes SE, Adams S, Perin MS. Histology/cytology discrepancies in HIV-infected obstetric patients with normal pap smears. Gynecol Oncol 1997; 65: 430–433.
24. Robinson WR, Luck MB, Kendall MA, Darragh TM. The predictive value of cytologic testing in women with the human immunodeficiency virus who have low-grade squamous cervical lesions: a study of a randomized, phase III chemoprevention trial. Am J Obstet Gynecol 2003; 188: 896–900.
25. Davey DD, Cox JT, Austin RM et al. Cervical cytology specimen adequacy: patient management guidelines and optimizing specimen collection. J Low Copy Res Tis Dis 2008; 12: 71–81.
26. Schweizer J, Lu PS, Mahoney CW et al. Feasibility study of a human papillomavirus EB oncoprotein test for diagnosis of cervical precancer and cancer. J Clin Microbiol 2010; 48: 4646–4648.
27. Kang M, Cu-Uvin S. Association of HIV viral load and CD4 cell count with human papillomavirus detection and clearance in HIV-infected women initiating highly active antiretroviral therapy. HIV Med 2012; 13: 372–378.
28. Minkoff H, Zhang Y, Burk RD et al. Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Infect Dis 2010; 201: 681–690.
29. Herrera R, Castle PE, Schiffman M et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005; 191: 1796–1807.
30. Gonzalez F, Hildesheim A, Rodriguez AC et al. Behavioral/lifestyle and immunologic factors associated with HPV infection among women older than 45 years. Cancer Epidemiol Biomarkers Prev 2010; 19: 3044–3054.
31. Benson CA, Kaplan JE, Masur H et al. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm Rep 2004; 53: 1–112.
32. Chiao EY, Giordano TP, Palefsky JM et al. Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis 2006; 43: 223–233.